{"commentary":{"count":16,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":7,"x_thread":5,"podcast":3,"x_video":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06769126\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT06769126","nct_id":"NCT06769126","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06769126. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Patients with ES-SCLC determined to be subtype A or N, and to be SLFN11 positive or patients with subtype P ES-SCLC.\n\nINDUCTION: Patients may receive a platinum compound plus etoposide per standard care as well as durvalumab IV over 60 minutes on day 1 of each cycle. Cycles repeat every 28 days for 4-6 cycles in the absence of disease progression or unacceptable toxicity.\n\nCONSOLIDATION: Patients may undergo thoracic radiation as clinically indicated.\n\nMAINTENANCE: Patients receive durvalumab IV over 60 minutes on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT scan or PET/CT scan and CT scan or MRI throughout the study. Patients also undergo tissue sample collection during screening and may undergo blood sample collection throughout the study.","label":"Cohort A, Arm 1 (durvalumab)","type":"EXPERIMENTAL"},{"description":"Patients with ES-SCLC determined to be subtype A or N, and to be SLFN11 positive or patients with subtype P ES-SCLC.\n\nINDUCTION: Patients may receive a platinum compound plus etoposide per standard care as well as durvalumab IV over 60 minutes on day 1 of each cycle. Cycles repeat every 28 days for 4-6 cycles in the absence of disease progression or unacceptable toxicity.\n\nCONSOLIDATION: Patients may undergo thoracic radiation as clinically indicated.\n\nMAINTENANCE: Patients receive durvalumab IV over 60 minutes on day 1 of each cycle and saruparib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT scan or PET/CT scan and CT scan or MRI throughout the study. Patients also undergo tissue sample collection during screening and may undergo blood sample collection throughout the study.","label":"Cohort A, Arm 2 (durvalumab, saruparib)","type":"EXPERIMENTAL"},{"description":"Patients with ES-SCLC determined to be subtype A or N, and to be SLFN11 negative.\n\nINDUCTION: Patients may receive a platinum compound plus etoposide per standard care as well as durvalumab IV over 60 minutes on day 1 of each cycle. Cycles repeat every 28 days for 4-6 cycles in the absence of disease progression or unacceptable toxicity.\n\nCONSOLIDATION: Patients may undergo thoracic radiation as clinically indicated.\n\nMAINTENANCE: Patients receive durvalumab IV over 60 minutes on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT scan or PET/CT scan and CT scan or MRI throughout the study. Patients also undergo tissue sample collection during screening and may undergo blood sample collection throughout the study.","label":"Cohort B, Arm 1 (durvalumab)","type":"EXPERIMENTAL"},{"description":"Patients with ES-SCLC determined to be subtype A or N, and to be SLFN11 negative.\n\nINDUCTION: Patients may receive a platinum compound plus etoposide per standard care as well as durvalumab IV over 60 minutes on day 1 of each cycle. Cycles repeat every 28 days for 4-6 cycles in the absence of disease progression or unacceptable toxicity.\n\nCONSOLIDATION: Patients may undergo thoracic radiation as clinically indicated.\n\nMAINTENANCE: Patients receive durvalumab IV over 60 minutes on day 8 and ceralasertib PO BID on days 1-7 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT scan or PET/CT scan and CT scan or MRI throughout the study. Patients also undergo tissue sample collection during screening and may undergo blood sample collection throughout the study.","label":"Cohort B, Arm 2 (durvalumab, ceralasertib)","type":"EXPERIMENTAL"},{"description":"Patients with ES-SCLC determined to be subtype I.\n\nINDUCTION: Patients may receive a platinum compound plus etoposide per standard care as well as durvalumab IV over 60 minutes on day 1 of each cycle. Cycles repeat every 28 days for 4-6 cycles in the absence of disease progression or unacceptable toxicity.\n\nCONSOLIDATION: Patients may undergo thoracic radiation as clinically indicated.\n\nMAINTENANCE: Patients receive durvalumab IV over 60 minutes on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT scan or PET/CT scan and CT scan or MRI throughout the study. Patients also undergo tissue sample collection during screening and may undergo blood sample collection throughout the study.","label":"Cohort C, Arm 1 (durvalumab)","type":"EXPERIMENTAL"},{"description":"Patients with ES-SCLC determined to be subtype I.\n\nINDUCTION: Patients may receive a platinum compound plus etoposide per standard care as well as durvalumab IV over 60 minutes on day 1 of each cycle. Cycles repeat every 28 days for 4-6 cycles in the absence of disease progression or unacceptable toxicity.\n\nCONSOLIDATION: Patients may undergo thoracic radiation as clinically indicated.\n\nMAINTENANCE: Patients receive durvalumab IV over 60 minutes on day 1 and monalizumab IV over 60 minutes on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT scan or PET/CT scan and CT scan or MRI throughout the study. Patients also undergo tissue sample collection during screening and may undergo blood sample collection throughout the study.","label":"Cohort C, Arm 2 (durvalumab, monalizumab)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2029-12-31","type":"ESTIMATED"},"conditions":["Extensive Stage Lung Small Cell Carcinoma","Lung Small Cell Carcinoma, A Subtype","Lung Small Cell Carcinoma, I Subtype","Lung Small Cell Carcinoma, N Subtype","Lung Small Cell Carcinoma, P Subtype"],"enrollment":{"count":900,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Biospecimen Collection","type":"PROCEDURE"},{"name":"Ceralasertib","type":"DRUG"},{"name":"Computed Tomography","type":"PROCEDURE"},{"name":"Durvalumab","type":"BIOLOGICAL"},{"name":"Etoposide","type":"DRUG"},{"name":"Magnetic Resonance Imaging","type":"PROCEDURE"},{"name":"Monalizumab","type":"BIOLOGICAL"},{"name":"Platinum Compound","type":"DRUG"},{"name":"Positron Emission Tomography","type":"PROCEDURE"},{"name":"Saruparib","type":"DRUG"},{"name":"Thoracic Radiation Therapy","type":"RADIATION"}],"last_update":"2026-03-30","lead_sponsor":"SWOG Cancer Research Network","official_title":"PRISM: PRecIsion in SCLC Via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab With or Without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2028-12-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Screen success rate (Screening)","timeFrame":"Up to 3 years"},{"measure":"Progression-free survival (PFS) (Cohort A)","timeFrame":"From date of randomization to treatment within a cohort to date of first documentation of progression, symptomatic deterioration, or death due to any cause, assessed up to 3 years"},{"measure":"PFS (Cohort B)","timeFrame":"From date of randomization to treatment within a cohort to date of first documentation of progression, symptomatic deterioration, or death due to any cause, assessed up to 3 years"},{"measure":"PFS (Cohort C)","timeFrame":"From date of randomization to treatment within a cohort to date of first documentation of progression, symptomatic deterioration, or death due to any cause, assessed up to 3 years"}],"references":[],"start_date":{"date":"2025-11-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study","url":"https://clinicaltrials.gov/study/NCT06769126"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06769126"}